Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System
Проблемы доставки лекарственных средств и современный прогресс в разработке офтальмологических терапевтических систем на основе нанопереносчиков
2022-01-28
SCID: 54.1/zk7vqrak
Discuss with AI
nanocarrier-based systemsnanoparticlesocular drug deliveryocular physiological barriersposterior segment delivery
Figures from the paper
Abstract (AI)
Drug instillation via a topical route is preferred since it is desirable and convenient due to the noninvasive and easy drug access to different segments of the eye for the treatment of ocular ailments. The low dose, rapid onset of action, low or no toxicity to the local tissues, and constrained systemic outreach are more prevalent in this route. The majority of ophthalmic preparations in the market are available as conventional eye drops, which rendered <5% of a drug instilled in the eye. The poor drug availability in ocular tissue may be attributed to the physiological barriers associated with the cornea, conjunctiva, lachrymal drainage, tear turnover, blood-retinal barrier, enzymatic drug degradation, and reflex action, thus impeding deeper drug penetration in the ocular cavity, including the posterior segment. The static barriers in the eye are composed of the sclera, cornea, retina, and blood-retinal barrier, whereas the dynamic barriers, referred to as the conjunctival and choroidal blood flow, tear dilution, and lymphatic clearance, critically impact the bioavailability of drugs. To circumvent such barriers, the rational design of the ocular therapeutic system indeed required enriching the drug holding time and the deeper permeation of the drug, which overall improve the bioavailability of the drug in the ocular tissue. This review provides a brief insight into the structural components of the eye as well as the therapeutic challenges and current developments in the arena of the ocular therapeutic system, based on novel drug delivery systems such as nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, in situ gel, dendrimers, contact lenses, implants, and microneedles. These nanotechnology platforms generously evolved to overwhelm the troubles associated with the physiological barriers in the ocular route. The controlled-drug-formulation-based strategic approach has considerable potential to enrich drug concentration in a specific area of the eye.
Key Findings
1
Controlled drug-delivery strategies can prolong ocular drug residence, enhance tissue permeation, and increase drug concentrations in specific ocular regions.
2
Nanocarrier-based systems, including nanomicelles, nanoparticles, nanosuspensions, liposomes, dendrimers, contact lenses, implants, and microneedles, are being developed to overcome ocular barriers.
3
Physiological barriers—including corneal and conjunctival barriers, tear turnover, drainage, enzymatic degradation, reflex action, and the blood-retinal barrier—limit ocular drug penetration and bioavailability.
4
Static and dynamic ocular barriers particularly impede drug delivery to deeper tissues and the posterior segment of the eye.
5
Topical ocular delivery is convenient and noninvasive, but conventional eye drops deliver less than 5% of the instilled drug into the eye.
Research Object
Nanocarrier-based ocular therapeutic systems (e.g., nanomicelles, nanoparticles, nanosuspensions, liposomes, in situ gels, dendrimers, drug-eluting contact lenses, implants, and microneedles) for topical eye drug delivery
Research Subject
strategies and current progress for overcoming ocular physiological barriers to improve drug retention, tissue penetration, bioavailability, and targeted drug concentration
Publication Details
Publication Date
2022-01-28
Journal
Publisher
ISSN
Cited by
209
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest